drugset
drugset / Trial / NCT05324631

A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Non-Radiographic Axial Spondyloarthritis

NCT05324631 ↗

Phase 3 Unknown 300 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is to evaluate the efficacy and safety of SHR0302 in subjects with active non-radiographic axial spondyloarthritis.

Timeline

Start
2022-08-16
Primary completion
2024-08-30
Completion
2024-12-11

Outcome

Met primary endpoint

release “硫酸艾玛昔替尼片对活动性放射学阴性中轴型脊柱关节炎具有统计学显著性和临床意义的改善，达到主要研究终点” hengrui.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR0302 Unknown — Oral

Indications

spondyloarthropathy